Allen Lutz has given his Buy rating due to a combination of factors including the strong brand equity of Hims & Hers Health and the strategic appointment of a new board member with significant industry experience. Despite the ongoing Federal Trade Commission (FTC) inquiry into the company's billing practices related to subscription cancellations and refunds, Lutz notes that such inquiries are fairly common in the industry and that the company is cooperating voluntarily, indicating a proactive approach to compliance and governance.